Summary: DPP-4 inhibitors were introduced in 2007 and as such are well known groups of incretin-based oral agents used in the treatment of type 2 diabetes. They are the best tolerated diabetes agents, with very low risk of hypoglycemia and neutral effect on body weight. They are preferred in vulnerable groups of patients eg. the elderly. Their efficacy is the greatest at the early stage of the disease, and tend to decrease over time. Due to their highly favorable safety profile and practical inability to cause hypoglycemia they have replaced sulfonylurea as second oral agents in type 2 diabetes treatment sequence (after metformin) in many countries. There is increasing evidence that using them early together with metformin (preferably as single pill combination) delays the need for treatment intensification by a few years. In Poland they have not been reimbursed until the end of 2022 ie. to the moment of patent expiry for sitagliptin and vildagliptin. Now the access to DPP-4 in Poland has significantly improved, and that will be of great benefit to Polish patients with type 2 diabetes.